Tango Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
Provided By GlobeNewswire
Last update: Nov 4, 2025
– Data update from vopimetostat (TNG462) showed 2L MTAP-del pancreatic cancer median progression free survival (mPFS) 7.2 months–
– Combination studies with RAS(ON) inhibitors ongoing, data anticipated 2026 –
Read more at globenewswire.com
